ResMed Outlines Growth Guidance and Strategy During Morgan Stanley Discussion

ResMed executives discussed the company's growth outlook, margin strategy, and portfolio plans during a meeting with Morgan Stanley. Chairman and CEO Mick Farrell stated that the company has issued guidance for 5% to 7% core constant-currency revenue growth. This guidance includes an estimated $75 million impact from the company's Astral field safety notice. Excluding this impact, the outlook implies 6.3% to 8.3% top-line growth, with the CFO characterizing the adjusted range as 6.5% to 8.5% growth.

The guidance outlines the company's expectations for its addressable market of 2.7 billion people worldwide. ResMed is actively seeking to increase referrals and convert more patients into long-term therapy through its various acquisitions and products.